CNS

BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s

BrainStorm Expands Patent Coverage of NurOwn Therapy for ALS, Parkinson’s

BrainStorm Cell Therapeutics is expanding the patent portfolio that protects its NurOwn technology for the treatment of several diseases affecting the central nervous system. The latest U.S. patent claim includes Parkinson’s disease and ALS (amyotrophic lateral sclerosis).

The announcement by BrainStorm follows a Notice of Allowance issued by the U.S. Patent and Trademark Office (USPTO) for the patent application (No. 14/173,846) titled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases.”

A Notice of Allowance indicates the invention qualifies for a patent. But additional fees and patent processes are required before the patent is fully protected. Until then, the patent is still considered as pending.

“We continue to protect our technology through strategic intellectual property [IP] achievements and this Notice of Allowance from the USPTO is a welcome addition to our IP portfolio,” Chaim Lebovits, CEO of BrainStorm, said in a press release.

The development of NurOwn started in the…